---
title: "Sito Bio's subsidiary chemical raw material drug maleate indacaterol has received the approval notice for its listing application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230949031.md"
description: "Sito Bio's holding subsidiary, Shandong Sruy Pharmaceutical Co., Ltd., recently received the notice of approval for the marketing application of Indacaterol Maleate chemical raw material from the National Medical Products Administration. This drug is a long-acting β2-adrenergic agonist, suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed dosage forms include inhalation powder aerosol, among others"
datetime: "2025-03-07T07:58:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230949031.md)
  - [en](https://longbridge.com/en/news/230949031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230949031.md)
---

# Sito Bio's subsidiary chemical raw material drug maleate indacaterol has received the approval notice for its listing application

According to the Zhitong Finance APP, Sito Bio (300583.SZ) announced that its holding subsidiary, Shandong Sry Pharmaceutical Co., Ltd., recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for Indacaterol Maleate issued by the National Medical Products Administration.

Indacaterol Maleate is a long-acting β2-adrenergic agonist that acts as a bronchodilator locally in the lungs after inhalation and is suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed formulations include inhalation preparations (single and compound), including Indacaterol Maleate inhalation powder and Indacaterol Bromide inhalation powder

### Related Stocks

- [300583.CN](https://longbridge.com/en/quote/300583.CN.md)

## Related News & Research

- [Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026](https://longbridge.com/en/news/286795160.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [09:03 ETOrthoArizona Expands Pinnacle Pain with New Chandler Facility and New Physician](https://longbridge.com/en/news/287070954.md)
- [05:20 ETThrough the America's Most Artistic Kid Competition, Colossal Raises $1.6 Million While Celebrating the Next Gen of Creative Visionaries](https://longbridge.com/en/news/287037755.md)
- [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md)